Industrial and Translational Research

RNA-editing therapeutics and drug-discovery bioinformatics

In my current role at ProQR Therapeutics, I lead and contribute to bioinformatics strategy for RNA-editing therapeutic programs in liver and CNS disease. My work supports therapeutic decision-making by analyzing RNA-seq, ADAR-mediated editing efficiency, target engagement, isoform effects, off-target signatures, safety-relevant transcriptomic changes, and biomarker signals.

The impact of this work is to make RNA-editing datasets interpretable and decision-ready for discovery teams. I help connect molecular readouts with disease biology, mechanism of action, candidate selection, lead prioritization, and translational planning.

• Support RNA-editing therapeutic programs across CNS and liver disease areas.
• Translate transcriptomic, targeted sequencing and functional readouts into biological recommendations.
• Build reproducible analysis workflows for editing efficiency, target engagement, isoform effects, off-target assessment and biomarker discovery.
• Help cross-functional teams evaluate candidate performance, biological risk and next-step experiments.
• Contribute pharmacodynamic and biological data analyses supporting IND-related development activities.

Reproducible computational platforms

I develop reproducible bioinformatics workflows using R, Python, Linux/HPC, Nextflow, automated quality-control reports, and structured data-management practices. The practical value is speed, consistency and confidence: project teams can compare results across experiments, understand analysis decisions, and use computational outputs for candidate prioritization and program strategy.

• Built scalable workflows for RNA-seq, RNA editing, off-target prediction and automated reporting.
• Improved reproducibility through version-controlled code, structured metadata, QC logic and standardized reporting.
• Supported cross-program knowledge transfer through FAIR data-management practices and protocol tracking.
• Helped make computational biology a project-facing scientific function rather than a downstream analysis service.

Translational pharmacology and PK/PD modeling

At Dr. Reddy's Laboratories, I worked in translational pharmacology and formulation-development support. I developed predictive statistical models, performed pharmacokinetic analyses, supported in vitro–in vivo interpretation, and contributed to bioequivalence-focused development programs in a regulated pharmaceutical R&D environment.

• Developed predictive models to estimate in vivo formulation performance.
• Performed pharmacokinetic analyses supporting preclinical and bioequivalence programs.
• Collaborated across formulation, pharmacokinetics, analytical, clinical and regulatory-facing teams.

Target, biomarker and mechanism-focused decision support

My contribution is strongest when biological systems cannot be understood from a single dataset or discipline. I bring together computational analysis, disease biology, pharmacology and translational thinking to clarify what the data show, what remains uncertain, and what evidence would change a program decision.